Health & Environmental Research Online (HERO)


Print Feedback Export to File
5022066 
Journal Article 
Safety And Efficacy Of Glycosylated Undenatured Type Ii Collagen (UC-II) In Obesearthritic Dogs 
Gupta, RC; Deparle, L; Canerdy, T; Goad, J; Bagchi, M; Bagchi, D 
2005 
1 
Toxicological Sciences
ISSN: 1096-6080
EISSN: 1096-0929 
84 
English 
In large breed dogs, arthritis is very common because of obesity, injury, aging, or immune disorder. This study was therefore undertaken to evaluate clinical tolerability and safety of UC-II in obese-arthritic dogs. Fifteen dogs in three groups received either no UC-II (Group I) or UC-II with 1 mg/day (Group II) or 10 mg/day (Group III) for 90 days. Lameness and pain were measured on a weekly basis for 120 days (90 days treatment plus 30 days post-treatment). Blood serum samples were assayed for rheumatoid factor (marker of arthritis); creatinine and blood urea nitrogen (markers of renal function); and alanine aminotransferase- and aspartate aminotransferase (markers of liver function). Dogs receiving 1 mg and 10 mg UCII/ day for 90 days showed marked decline in pain and lameness after physical exertion, and the therapeutic efficacy was dose-dependent. UC-II at either dose did not produce any side effects or significant changes in serum chemistry, and was well tolerated. In addition, dogs receiving UC-II for 90 days showed increased activity level and lost a significant amount of body weight. Following UC-II withdrawal for a period of 30 days, all dogs experienced a relapse of overall pain, pain with limb manipulation, and exercise-associated lameness. These results suggest that daily treatment of arthritic dogs with UC-II ameliorates signs and symptoms of arthritis, and UC-II is well tolerated with no adverse effects.